Episode 154: New Drug Approvals for Metastatic Castration-Sensitive Prostate Cancer

Andrew Ruplin, PharmD, clinical instructor and oncology clinical pharmacist at Seattle Cancer Care Alliance and the University of Washington in Seattle, joins Stephanie Jardine, BSN, RN, oncology clinical specialist at ONS, to discuss new drug approvals for metastatic castration-sensitive prostate cancer. Astellas and Pfizer Inc. provided support for this podcast episode through an educational grant.

Music Credit: "Fireflies and Stardust" by Kevin MacLeod  

Licensed under Creative Commons by Attribution 3.0 

Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by May 7, 2023. The planners and faculty for this episode have no conflicts to disclose, and the episode has no commercial support. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center’s Commission on Accreditation. 

Episode Notes 

Check out these resources from today’s episode:  

To discuss the information in this episode with other oncology nurses, visit the ONS Communities.

To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.

Listen on:

Listen on Amazon Music, Listen on Apple Podcasts, Listen on Spotify, Listen on YouTube Music

ONS Podcasts

On-the-go discussions covering a wide array of clinical and leadership topics that you can earn NCPD for.

View All Podcasts